Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABCD Study Results: Will Noninvasive T-Wave Test Boost ICD Referrals?

This article was originally published in The Gray Sheet

Executive Summary

Data presented Nov. 15 helps validate microvolt t-wave alternans (MTWA) analysis for identifying certain patients at high risk for sudden cardiac death, but questions remain about the test's potential impact on physician practice

You may also be interested in...



HRS Features Data On ICD Survival, MRI-Safe Pacers, Device Replacements

Encouraging results on defibrillator survival rates and imaging-safe pacemakers, along with more detailed outcomes data from device replacements, were among the biggest take-away items from the Heart Rhythm Society's annual scientific sessions held in Boston earlier this month

HRS Features Data On ICD Survival, MRI-Safe Pacers, Device Replacements

Encouraging results on defibrillator survival rates and imaging-safe pacemakers, along with more detailed outcomes data from device replacements, were among the biggest take-away items from the Heart Rhythm Society's annual scientific sessions held in Boston earlier this month

T-Wave Alternans ICD Screening May Gain Traction With St. Jude Pact

St. Jude Medical's endorsement of microvolt t-wave alternans testing under a co-marketing agreement with test maker Cambridge Heart will help accelerate adoption of the technology, which guides appropriate defibrillator patient selection, both companies say

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel